Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000993058 | SCV001145766 | uncertain significance | not provided | 2019-01-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003311931 | SCV004297093 | pathogenic | Hereditary spastic paraplegia 3A | 2022-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 347 of the ATL1 protein (p.Met347Thr). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Met347 amino acid residue in ATL1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21321493, 25637064). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATL1 protein function. ClinVar contains an entry for this variant (Variation ID: 805504). This missense change has been observed in individuals with autosomal dominant hereditary spastic paraplegia (PMID: 21321493, 25637064). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). |
Inherited Neuropathy Consortium Ii, |
RCV003311931 | SCV004011931 | uncertain significance | Hereditary spastic paraplegia 3A | 2016-01-06 | no assertion criteria provided | literature only |